Q1 Earnings Estimate for RVPH Issued By Roth Capital

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities research analysts at Roth Capital issued their Q1 2026 earnings per share estimates for shares of Reviva Pharmaceuticals in a report issued on Friday, April 4th. Roth Capital analyst B. Pachaiyappan expects that the company will earn ($0.16) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Roth Capital also issued estimates for Reviva Pharmaceuticals’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.19) EPS.

Several other equities research analysts also recently issued reports on the company. HC Wainwright dropped their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price objective on the stock. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, January 10th. Finally, D. Boral Capital decreased their target price on shares of Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $10.00.

Reviva Pharmaceuticals Trading Down 5.9 %

Shares of RVPH stock opened at $0.53 on Monday. Reviva Pharmaceuticals has a 12 month low of $0.49 and a 12 month high of $4.28. The stock has a market capitalization of $17.72 million, a P/E ratio of -0.48 and a beta of 0.05. The firm’s 50 day moving average is $1.40 and its 200 day moving average is $1.45.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Monday, March 31st. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RVPH. Tang Capital Management LLC bought a new stake in Reviva Pharmaceuticals during the fourth quarter worth about $308,000. Ameriprise Financial Inc. bought a new position in Reviva Pharmaceuticals during the fourth quarter valued at approximately $84,000. Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals by 17.9% during the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after acquiring an additional 42,376 shares in the last quarter. EMC Capital Management lifted its holdings in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after acquiring an additional 26,134 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals in the 4th quarter valued at $45,000. 63.18% of the stock is owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.